Home › Markets › Health Care › ANIP

ANI Pharmaceuticals Inc. (ANIP)

ANIP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$70.84
-3.74% on the day
Market cap
$1.6B
Small cap
Revenue · 2025
$883.4M
+43.8% on 2024
Net income · 2025
$78.0M
8.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerANIP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001023024
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$883.4M
Net income$78.0M
Operating income$111.1M
Net margin8.8%
Operating margin12.6%
Revenue growth+43.8%
Cash$285.6M
Total assets$1.4B
P/E (computed)20.9×
P/S (computed)1.8×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52023-05-12
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-08-07
Latest current report8-K2026-08-24
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.5%
1 month-2.7%
3 months-14.4%
Year to date-11.1%
1 year-20.8%
From 52-week high-26.4%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZBIOZenas BioPharma Inc.$25.16-4.70%$1.6B
NUVBNuvation Bio Inc.$4.72-3.67%$1.7B
GPCRStructure Therapeutics Inc.$22.31-6.69%$1.6B
OCULOcular Therapeutix Inc.$7.24-4.23%$1.6B
GENBGenerate Biomedicines Inc.$12.26-11.45%$1.6B
MRVIMaravai LifeSciences Holdings Inc.$6.53-7.51%$1.7B
SEPNSepterna Inc.$36.41-3.05%$1.7B
CMPSCOMPASS Pathways Plc American Depository Shares$11.14-3.38%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier